Celcuity Inc. CELC
69.26 USD -0.46 (-0.66%)
Nov 4, 2026, 11:10 AM EST
67.48 Day range 72.00
53.54 52-week range 151.02
- YTD
- -30.56%
- 1 year
- -5.11%
News
globenewswire.com Celcuity To Participate in Upcoming Investor Conferences MINNEAPOLIS, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid…
seekingalpha.com Celcuity: Stronger Clinical Evidence, Much Lower Valuation Celcuity Inc. retains a Buy rating after REVTORPYK's FDA approval and robust mutant data, despite a significant share price drop. REVTORPYK demonstrated strong efficacy and safety, especially versus…
globenewswire.com Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call MINNEAPOLIS, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of…
globenewswire.com Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026 Median PFS was 21.5 months with the gedatolisib triplet and 11.5 months with the gedatolisib doublet versus 9.1 months with alpelisib + fulvestrant in patients who had no liver metastases
globenewswire.com Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026 Median radiographic progression free survival (“rPFS”) was 15.7 months and the six-month rPFS rate (“rPFS6”) was 82.2% in patients who received prior abiraterone
benzinga.com Cantor Fitzgerald Initiates Coverage On Celcuity with Overweight Rating, Announces Price Target of $140 Cantor Fitzgerald analyst Li Watsek initiates coverage on Celcuity (NASDAQ:CELC) with a Overweight rating and announces Price Target of $140.
zacks.com New Strong Sell Stocks for October 14th ADDYY, CELC and CNL have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2026.
globenewswire.com Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026 Rapid oral presentation of additional sub-group analyses from the VIKTORIA-1 PIK3CA mutant-type cohort Poster presentation of a comparative analysis of data for the gedatolisib triplet from the…
globenewswire.com Celcuity Appoints David Gryska To Its Board Of Directors Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity's Board Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity's Board
defenseworld.net Celcuity (NASDAQ:CELC) Shares Gap Up – Time to Buy? Celcuity, Inc. (NASDAQ: CELC - Get Free Report)'s share price gapped up prior to trading on Wednesday. The stock had previously closed at $77.38, but opened at $81.30. Celcuity shares last traded at…
fool.com Why Celcuity Stock Was a Winner on Wednesday This is a breast cancer treatment, Revtorpyk. It was approved by the FDA in July.
benzinga.com Needham Maintains Buy on Celcuity, Lowers Price Target to $134 Needham analyst Gil Blum maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $140 to $134.- benzinga.com Celcuity Announces Commercial Availability Of REVTORPYK In U.S. For People With Hormone Receptor-Positive Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that…
globenewswire.com Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States REVTORPYK is indicated for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation detected following progression on or after at least one line of endocrine therapy in the metastatic…
benzinga.com JP Morgan Initiates Coverage On Celcuity with Overweight Rating, Announces Price Target of $157 JP Morgan analyst Anupam Rama initiates coverage on Celcuity (NASDAQ:CELC) with a Overweight rating and announces Price Target of $157.
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
seekingalpha.com Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript
globenewswire.com Celcuity To Participate in Upcoming Investor Conferences MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid…
benzinga.com Celcuity Files Supplemental New Drug Application To FDA For REVTORPYK To Treat Breast Cancer Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its…
globenewswire.com Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications,…
defenseworld.net Brandywine Managers LLC Acquires New Stake in Celcuity, Inc. $CELC Brandywine Managers LLC acquired a new stake in shares of Celcuity, Inc. (NASDAQ: CELC) in the second quarter, according to the company in its most recent filing with the Securities and Exchange…
benzinga.com Guggenheim Maintains Buy on Celcuity, Raises Price Target to $175 Guggenheim analyst Brad Canino maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price target from $165 to $175.
benzinga.com Citizens Reiterates Market Outperform on Celcuity, Maintains $177 Price Target Citizens analyst Silvan Turkcan reiterates Celcuity (NASDAQ:CELC) with a Market Outperform and maintains $177 price target.
benzinga.com HC Wainwright & Co. Reiterates Buy on Celcuity, Maintains $155 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $155 price target.
seekingalpha.com Celcuity: REVTORPYK Is Now A Commercial Story Celcuity Inc. remains a Buy as the REVTORPYK/gedatolisib FDA approval and rapid NCCN Category 1 inclusion de-risk clinical and commercial adoption. CELC's financials reflect a front-loaded commercial…
benzinga.com Celcuity Analysts Slash Their Forecasts After Q2 Loss Celcuity Inc (NASDAQ:CELC) reported a narrower-than-expected loss for the second quarter on Thursday.
benzinga.com Celcuity Analysts Slash Their Forecasts After Q2 Loss Celcuity Inc (NASDAQ:CELC) reported better-than-expected Q2 losses of $1.07 per share. Analysts are optimistic with price target cuts by Needham and Stifel.- benzinga.com Stifel Maintains Buy on Celcuity, Lowers Price Target to $150 Stifel analyst Stephen Willey maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $175 to $150.
- benzinga.com Needham Maintains Buy on Celcuity, Lowers Price Target to $140 Needham analyst Gil Blum maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $157 to $140.
seekingalpha.com Celcuity Inc. (CELC) Q2 2026 Earnings Call Transcript Celcuity Inc. (CELC) Q2 2026 Earnings Call Transcript
marketbeat.com Celcuity Q2 Earnings Call Highlights Celcuity NASDAQ: CELC said it remains on track to begin commercial shipments of REVTORPYK, its gedatolisib therapy for certain patients with advanced breast cancer, late in the third quarter of 2026…
benzinga.com Celcuity Reports Q2 2026 Results: Full Earnings Call Transcript On Thursday, Celcuity (NASDAQ:CELC) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call…- benzinga.com Celcuity Q2 Adj. EPS $(1.07) Beats $(1.17) Estimate Celcuity (NASDAQ:CELC) reported quarterly losses of $(1.07) per share which beat the analyst consensus estimate of $(1.17) by 7.76 percent. This is a 15.05 percent decrease over losses of $(0.93) per…
globenewswire.com Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid…
benzinga.com Celcuity's REVTORPYK Receives Recommendation From National Comprehensive Cancer Network Clinical Practice Guidelines In Oncology As Preferred Category 1 Second-Line Therapy Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced that REVTORPYK™ (gedatolisib)…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers China Pharma Holding (AMEX:CPHI) shares moved upwards by 67.6% to $1.03 during Wednesday's regular session. The market value of their outstanding shares is at $24.9 million. Conexeu Sciences…- benzinga.com Citizens Maintains Market Outperform on Celcuity, Raises Price Target to $177 Citizens analyst Silvan Turkcan maintains Celcuity (NASDAQ:CELC) with a Market Outperform and raises the price target from $160 to $177.
benzinga.com CrowdStrike To Rally Over 12%? Here Are 10 Top Analyst Forecasts For Wednesday Top Wall Street analysts changed outlook on top names. See all changes, including upgrades/downgrades, on our analyst ratings page.- benzinga.com HC Wainwright & Co. Maintains Buy on Celcuity, Raises Price Target to $155 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price target from $145 to $155.
benzinga.com Palo Alto Networks To Rally Nearly 70%? Here Are 10 Notable Analyst Calls From Wednesday Top Wall Street analysts changed outlook on top names. For all rating changes, upgrades and downgrades, visit analyst ratings page.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Earnings Scheduled For May 14, 2026 
benzinga.com Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big Stocks Moving Higher On Monday Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday after reporting better-than-expected financial results. Other top gainers included companies like…
benzinga.com This Prudential Financial Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday Wall Street analysts changed outlook on top names, including PRU, ARE, TRGP, VITL, and GOOGL. See analyst ratings page for more info.- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com This First Tracks Biotherapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday Top Wall Street analysts changed outlook on top stocks. See analyst ratings page for changes, including upgrades, downgrades, and initiations.
benzinga.com This Airbnb Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday Wall Street analysts upgraded and raised price targets for ESS, SITE, PKG, ABNB, and CELC. See what other analysts think before buying ABNB stock.
benzinga.com Packaging Corp Of America To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday Needham analyst Rick Patel maintained a Buy rating. Steven Madden shares closed at $47.27 on Friday. Top analysts change outlook on BTSG, CELC, ESS, CORT, PKG, PRU, RVTY, and SHOO. See how they rate…
benzinga.com Why eBay Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket eBay (NASDAQ: EBAY) rose sharply after GameStop (NYSE: GME) proposed to acquire it for $125/share, valuing GME at $55.5B. eBay shares jumped 8.1% to $112.50 in pre-market trading.- benzinga.com Earnings Scheduled For March 25, 2026